J&J Investigational NNRTI Shows Promise Against Resistant HIV
This article was originally published in The Pink Sheet Daily
Phase IIb data shows activity of TMC125 against NNRTI-resistant virus.
You may also be interested in...
The protease inhibitor – formerly known as TMC-114 – is to be co-administered with a low dose of ritonavir.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.